Literature DB >> 23992440

Structure and function of midkine as the basis of its pharmacological effects.

T Muramatsu1.   

Abstract

UNLABELLED: Midkine (MK) is a heparin-binding growth factor or cytokine and forms a small protein family, the other member of which is pleiotrophin. MK enhances survival, migration, cytokine expression, differentiation and other activities of target cells. MK is involved in various physiological processes, such as development, reproduction and repair, and also plays important roles in the pathogenesis of inflammatory and malignant diseases. MK is largely composed of two domains, namely a more N-terminally located N-domain and a more C-terminally located C-domain. Both domains are basically composed of three antiparallel β-sheets. In addition, there are short tails in the N-terminal and C-terminal sides and a hinge connecting the two domains. Several membrane proteins have been identified as MK receptors: receptor protein tyrosine phosphatase Z1 (PTPζ), low-density lipoprotein receptor-related protein, integrins, neuroglycan C, anaplastic lymphoma kinase and Notch-2. Among them, the most established one is PTPζ. It is a transmembrane tyrosine phophatase with chondroitin sulfate, which is essential for high-affinity binding with MK. PI3K and MAPK play important roles in the downstream signalling system of MK, while transcription factors affected by MK signalling include NF-κB, Hes-1 and STATs. Because of the involvement of MK in various physiological and pathological processes, MK itself as well as pharmaceuticals targeting MK and its signalling system are expected to be valuable for the treatment of numerous diseases. LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  Notch-2; anaplastic lymphoma kinase; low-density lipoprotein receptor-related protein 1; midkine; pleiotrophin; receptor protein tyrosine phosphatase Z1

Mesh:

Substances:

Year:  2014        PMID: 23992440      PMCID: PMC3925020          DOI: 10.1111/bph.12353

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  123 in total

1.  Midkine promotes tetraspanin-integrin interaction and induces FAK-Stat1alpha pathway contributing to migration/invasiveness of human head and neck squamous cell carcinoma cells.

Authors:  Yiping Huang; Myoung Sook-Kim; Edward Ratovitski
Journal:  Biochem Biophys Res Commun       Date:  2008-10-11       Impact factor: 3.575

2.  Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta.

Authors:  Constantinos Mikelis; Evanthia Sfaelou; Marina Koutsioumpa; Nelly Kieffer; Evangelia Papadimitriou
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

3.  Midkine accumulated in nucleolus of HepG2 cells involved in rRNA transcription.

Authors:  Li-Cheng Dai; Jian-Zhong Shao; Li-Shan Min; Yong-Tao Xiao; Li-Xin Xiang; Zhi-Hong Ma
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

4.  Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine.

Authors:  Shintaro Ohgake; Eiji Shimizu; Kenji Hashimoto; Naoe Okamura; Kaori Koike; Hiroyuki Koizumi; Mihisa Fujisaki; Nobuhisa Kanahara; Shingo Matsuda; Chihiro Sutoh; Daisuke Matsuzawa; Hisako Muramatsu; Takashi Muramatsu; Masaomi Iyo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-02-13       Impact factor: 5.067

5.  The growth factor midkine regulates the renin-angiotensin system in mice.

Authors:  Akinori Hobo; Yukio Yuzawa; Tomoki Kosugi; Noritoshi Kato; Naoto Asai; Waichi Sato; Shoichi Maruyama; Yasuhiko Ito; Hiroyuki Kobori; Shinya Ikematsu; Akira Nishiyama; Seiichi Matsuo; Kenji Kadomatsu
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

6.  Receptor type protein tyrosine phosphatase zeta-pleiotrophin signaling controls endocytic trafficking of DNER that regulates neuritogenesis.

Authors:  Nobuna Fukazawa; Seisuke Yokoyama; Mototsugu Eiraku; Mineko Kengaku; Nobuaki Maeda
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

7.  Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes.

Authors:  Yiping Huang; Mohammad Obaidul Hoque; Feng Wu; Barry Trink; David Sidransky; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2008-03-16       Impact factor: 4.534

8.  Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.

Authors:  Pablo Perez-Pinera; Wei Zhang; Yunchao Chang; Jose Antonio Vega; Thomas F Deuel
Journal:  J Biol Chem       Date:  2007-08-06       Impact factor: 5.157

9.  Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population.

Authors:  Jinyan Wang; Hideyuki Takeuchi; Yoshifumi Sonobe; Shijie Jin; Tetsuya Mizuno; Shin Miyakawa; Masatoshi Fujiwara; Yoshikazu Nakamura; Takuma Kato; Hisako Muramatsu; Takashi Muramatsu; Akio Suzumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-04       Impact factor: 11.205

10.  Midkine-b regulates cell specification at the neural plate border in zebrafish.

Authors:  Daniel Liedtke; Christoph Winkler
Journal:  Dev Dyn       Date:  2008-01       Impact factor: 3.780

View more
  29 in total

1.  Midkine is a dual regulator of wound epidermis development and inflammation during the initiation of limb regeneration.

Authors:  Stephanie L Tsai; Clara Baselga-Garriga; Douglas A Melton
Journal:  Elife       Date:  2020-01-14       Impact factor: 8.140

2.  Pleiotrophin, a multifunctional cytokine and growth factor, induces leukocyte responses through the integrin Mac-1.

Authors:  Di Shen; Nataly P Podolnikova; Valentin P Yakubenko; Christopher L Ardell; Arnat Balabiyev; Tatiana P Ugarova; Xu Wang
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

Review 3.  From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.

Authors:  Noah Sorrelle; Adrian T A Dominguez; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2017-03-29       Impact factor: 4.962

4.  Ethanol activates midkine and anaplastic lymphoma kinase signaling in neuroblastoma cells and in the brain.

Authors:  Donghong He; Hu Chen; Hisako Muramatsu; Amy W Lasek
Journal:  J Neurochem       Date:  2015-08-11       Impact factor: 5.372

5.  Midkine-Notch2 Pathway Mediates Excessive Proliferation of Airway Smooth Muscle Cells in Chronic Obstructive Lung Disease.

Authors:  Tang Deng; Qifeng Huang; Kaiwen Lin; Jin Qian; Qi Li; Lihua Li; Shuangqin Xu; Hongfang Yun; Hangfei Wang; Xinxin Wu; Heng Liu; Guiyun Jin; Xiaoran Liu
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

Review 6.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

7.  Midkine: an emerging target of drug development for treatment of multiple diseases.

Authors:  Takashi Muramatsu; Kenji Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  Midkine in vitamin D deficiency and its association with anti-Saccharomyces cerevisiae antibodies.

Authors:  F B Serinkan Cinemre; Hakan Cinemre; Cengiz Karacaer; Birsen Aydemir; Ahmet Nalbant; Tezcan Kaya; Ali Tamer
Journal:  Inflamm Res       Date:  2015-11-13       Impact factor: 4.575

9.  Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy.

Authors:  Yuichi J Shimada; Kohei Hasegawa; Stephanie M Kochav; Pouya Mohajer; Jeeyoun Jung; Mathew S Maurer; Muredach P Reilly; Michael A Fifer
Journal:  J Cardiovasc Transl Res       Date:  2019-07-05       Impact factor: 4.132

Review 10.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.